A mathematical model of the impact of novel treatments on the A\03B2 burden in the Alzheimer's brain, CSF and plasma

by Lawrence M. Wein

With the advent of novel therapies for AD, there is a pressing need for biomarkers that are easy to monitor, such as the amyloid-beta levels in the cerebrospinal fluid (CSF) and plasma. To gain a better understanding of the explanatory power of these biomarkers, we formulate and analyze a compartmental mathematical model for the amyloid-beta accumulation in the brain, CSF and plasma throughout the course of Alzheimer's treatment. Our analysis reveals that the total amyloid-beta burden in the brain is dictated by a unitless quantity called the polymerization ratio, which is the product of...